Quantitative HBcrAg and HBcAb versus HBsAg and HBV DNA in predicting liver fibrosis levels of chronic hepatitis B patients

Schweitzer, 2015, Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013, Lancet, 386, 1546, 10.1016/S0140-6736(15)61412-X Ginzberg, 2018, Global HBV burden: guesstimates and facts, Hepatol Int, 12, 315, 10.1007/s12072-018-9884-8 Pan, 2005, Natural history and clinical consequences of hepatitis B virus infection, Int J Med Sci, 2, 36, 10.7150/ijms.2.36 Ieluzzi, 2014, Progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in chronic hepatitis B patients in Italy, Dig Liver Dis, 46, 427, 10.1016/j.dld.2014.01.003 Golsaz-Shirazi, 2018, Immune function of plasma cytoid dendritic cells, natural killer cells, and their crosstalk in HBV infection, Rev Med Virol, 28, e2007, 10.1002/rmv.2007 Yang, 2018, The immunologic role of gut microbiota in patients with chronic HBV infection, J Immunol Res, 2018, 2361963, 10.1155/2018/2361963 Hadziyannis, 2018, Viral biomarkers in chronic HBeAg negative HBV infection. Genes (Basel), 9 Mak, 2019, Novel developments of hepatitis B: treatment goals, agents and monitoring tools, Expert Rev Clin Pharmacol, 12, 109, 10.1080/17512433.2019.1567327 Seto, 2012, High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B, PLoS One, 7, e43087, 10.1371/journal.pone.0043087 Martinot-Peignoux, 2013, Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients, J Hepatol, 58, 1089, 10.1016/j.jhep.2013.01.028 Cheng, 2013, Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B, J Clin Virol, 57, 323, 10.1016/j.jcv.2013.04.012 Xun, 2013, Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers, J Gastroenterol Hepatol, 28, 1746, 10.1111/jgh.12304 Wang, 2014, Comparison of hepatitis B surface antigen and e antigen in predicting liver histology in hepatitis B e antigen-positive chronic hepatitis B patients, Hepatol Int, 8, 216, 10.1007/s12072-013-9502-8 Zeng, 2015, Serum HBsAg and HBeAg levels are associated with liver pathological stages in the immune clearance phase of hepatitis B virus chronic infection, Mol Med Rep, 11, 3465, 10.3892/mmr.2015.3207 Goyal, 2015, HBsAg level as predictor of liver fibrosis in HBeAg positive patients with chronic hepatitis B virus infection, J Clin Exp Hepatol, 5, 213, 10.1016/j.jceh.2015.04.008 Chakrabarty, 2018, Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?, J Viral Hepat, 25, 80, 10.1111/jvh.12756 Zhang, 2018, Performance evaluation of HBsAg by Lumipulse HBsAg-HQ: The agreement with HBsAg by Architect HBsAg-QT and the effectiveness in predicting liver tissue pathological states of chronic hepatitis B patients, Adv Clin Exp Med, 27, 1045, 10.17219/acem/69247 Papatheodoridis, 2008, Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?, Hepatology, 48, 1451, 10.1002/hep.22518 Praneenararat, 2014, HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication, BMC Gastroenterol, 14, 218, 10.1186/s12876-014-0218-6 McMahon, 2014, Relationship between level of hepatitis B virus DNA and liver disease: a population-based study of hepatitis B e antigen-negative persons with hepatitis B, Clin Gastroenterol Hepatol, 12, 701, 10.1016/j.cgh.2013.09.005 Alam, 2014, Hepatic necro-inflammation and severe liver fibrosis in patients with chronic hepatitis B with undetectable HBV DNA and persistently normal alanine aminotransferase, Bangladesh Med Res Counc Bull, 40, 92, 10.3329/bmrcb.v40i3.25229 Zhang, 2016, Measurement of the hepatitis B core-related antigen is valuable for predicting the pathological status of liver tissues in chronic hepatitis B patients, J Virol Methods, 235, 92, 10.1016/j.jviromet.2016.05.016 Li, 2018, Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels, Hepatol Res, 48, E133, 10.1111/hepr.12937 Li MR, Lu JH, Ye LH, Sun XL, Zheng YH, Liu ZQ, Zhang HC, Liu YY, Lv Y, Huang Y, Dai EH.Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naïve chronic hepatitis B patients. Medicine (Baltimore), 95:e4422. Zhou, 2017, Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase. Sci Rep, 7, 2747 Li, 2018, novel noninvasive index for the prediction of moderate to severe fibrosis in chronic hepatitis B patients, Dig Liver Dis, 50, 482, 10.1016/j.dld.2017.12.028 Li, 2017, Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B. Oncotarget, 8, 11063 Li, 2018, Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-naïve CHB patients, J Chin Med Assoc, 81, 1052, 10.1016/j.jcma.2018.05.007 Terrault, 2018, Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Hepatology, 67, 1560, 10.1002/hep.29800 Lampertico, 2017, EASL. 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, J Hepatol, 67, 370, 10.1016/j.jhep.2017.03.021 Sarin, 2016, Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update, Hepatol Int, 10, 1, 10.1007/s12072-015-9675-4 World Health Organization. Guidelines for the prevention, care and treatmentof persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015. Brunt, 2000, Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond, Hepatology, 31, 241, 10.1002/hep.510310136 Zhang, 2019, Performance of hepatitis B core-related antigen versus hepatitis B surface antigen and hepatitis B virus DNA in predicting HBeAg-positive and HBeAg-negative chronic hepatitis, Ann Lab Med, 39, 67, 10.3343/alm.2019.39.1.67 Desmet, 2004, Cirrhosis reversal: a duel between dogma and myth, J Hepatol, 40, 860, 10.1016/j.jhep.2004.03.007 Calvaruso, 2014, Regression of fibrosis after HBV antiviral therapy, Is cirrhosis reversible?. Liver Int, 34, 85, 10.1111/liv.12395 Ohkoshi, 2016, Natural regression of fibrosis in chronic hepatitis B, World J Gastroenterol, 22, 5459, 10.3748/wjg.v22.i24.5459 Jung, 2017, Reversal of liver cirrhosis: current evidence and expectations, Korean J Intern Med, 32, 213, 10.3904/kjim.2016.268